Lantheus Holdings Inc (OQ:LNTH)

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: 331 Treble Cove Rd
NORTH BILLERICA MA 01862
Tel: 1-978-6718842
Website: https://www.lantheus.com
IR: See website
<
Key People
Mary Anne Heino
Chairman of the Board
Paul M. Blanchfield
President
Brian A. Markison
Chief Executive Officer, Director
Robert J. Marshall
Chief Financial Officer, Treasurer
Daniel M. Niedzwiecki
Chief Administrative Officer, General Counsel, Corporate Secretary
Jeffrey Humphrey
Chief Medical Officer
Etienne Montagut
Chief Business Officer
Amanda Morgan
Chief Commercial Officer
Jean-Claude Provost
Chief Medical Officer
Business Overview
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others.
Financial Overview
For the three months ended 31 March 2024, Lantheus Holdings Inc revenues increased 23% to $370M. Net income totaled $131.1M vs. loss of $2.8M. Revenues reflect PYLARIFY segment increase of 32% to $258.9M, DEFINITY segment increase of 11% to $76.6M. Net Income reflects Interest Income increase from $3.5M to $8.5M (income), Foreign currency losses increase from $246K (expense) to $217K (income).
Employees: 834 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $5,589M as of Mar 31, 2024
Annual revenue (TTM): $1,366M as of Mar 31, 2024
EBITDA (TTM): $535.24M as of Mar 31, 2024
Net annual income (TTM): $460.53M as of Mar 31, 2024
Free cash flow (TTM): $204.99M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 69,312,588 as of Apr 25, 2024
Index Membership: S&P 400 Mid Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.